Literature DB >> 3219472

Nifedipine kinetics in the rat and relationship between its serum concentrations and uterine and cardiovascular effects.

S J Downing1, M Hollingsworth.   

Abstract

1. The kinetics of nifedipine and the relationship between its serum concentration and uterine and cardiovascular effects were investigated in 3 groups of animals. These were ovariectomized (ovx) anaesthetized non-pregnant rats following bolus i.v. injection (400 micrograms kg-1) and during 300 min infusion (10 micrograms kg-1 min-1) and ovx, progesterone-treated late pregnant rats during infusion. Also, the kinetics were determined in ovary-intact late pregnant rats following bolus i.v. injection (400 micrograms kg-1). 2. Measurement of serum nifedipine concentrations after bolus i.v. injection in ovx non-pregnant rats showed a biexponential decay with time from which the following parameters were calculated: V beta = 300 +/- 30 ml kg-1; rate constants k12 = 0.51 +/- 0.18 min-1; k21 = 0.07 +/- 0.02 min-1; ke1 = 0.10 +/- 0.05 min-1; elimination clearance = 2.4 +/- 0.2 (ml min-1) kg-1; t1/2 alpha = 2.5 +/- 1.0 min; t1/2 beta = 102 +/- 15 min. In intact pregnant rats, a biexponential decay of serum nifedipine concentrations with time was also observed after bolus i.v. administration with similar parameters to non-pregnant animals. These kinetic parameters, used to calculate serum nifedipine concentrations obtained during infusion, predicted values similar to experimental values for 180 min, but thereafter slightly underestimated experimental values. 3. Immediate reductions in uterine contractions, mean blood pressure and heart rate were observed following bolus i.v. injection of nifedipine to ovx non-pregnant rats, with returns towards control values as serum nifedipine concentrations declined. IC15 values (15% change from baseline), calculated from log10 serum concentration-response curves, of 0.3 +/- 0.05 micrograms ml-1 for inhibition of uterine contractions, 0.8 +/- 0.3 micrograms ml-1 for depression of blood pressure and 3.8 +/- 1.0 micrograms ml-1 for reduction in heart rate were obtained. 4. In ovx non-pregnant rats, nifedipine infusion produced a maximum reduction in integral of uterine contractions of 70% by 120 min and a maximum reduction of 15% in heart rate. Mean blood pressure was not significantly different from vehicle-treated rats. IC15 values were 0.7 +/- 0.1 micrograms ml-1 and 2.8 +/- 0.6 micrograms ml-1 for inhibition of uterine contractions and heart rate respectively. 5. In ovx, progesterone-treated late pregnant rats, nifedipine infusion produced similar serum concentrations to those of non-pregnant rats but completely abolished uterine contractions by 70 min. Maximum reductions of 30% in heart rate and blood pressure were observed. IC1S values were 0.5 + 0.1ygml-1 for uterine contractions, 0.9 + 0.3lpgmlP1 for blood pressure and 1.2 +/- 0.3 pg ml - 1 for heart rate. 6. The findings suggest that the kinetics of nifedipine are similar in pregnant and non-pregnant rats and support the idea that the drug exerts a slight selectivity for uterine inhibition relative to cardiovascular effects. The uterus of the late pregnant rat appears to be more sensitive to nifedipine than that of the non-pregnant animal.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3219472      PMCID: PMC1854145          DOI: 10.1111/j.1476-5381.1988.tb16544.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  24 in total

1.  Increase by oestrogen of calcium entry and calcium channel density in uterine smooth muscle.

Authors:  S Batra
Journal:  Br J Pharmacol       Date:  1987-10       Impact factor: 8.739

2.  Hormonal regulation of myometrial calcium transport.

Authors:  M E Carsten
Journal:  Gynecol Invest       Date:  1974

3.  Oral ethanol ingestion altered nifedipine pharmacokinetics in the rat: a preliminary study.

Authors:  K M Boje; J A Dolce; H L Fung
Journal:  Res Commun Chem Pathol Pharmacol       Date:  1984-11

4.  The significance of changes in tissue clearing-factor lipase activity in relation to the lipaemia of pregnancy.

Authors:  S Otway; D S Robinson
Journal:  Biochem J       Date:  1968-02       Impact factor: 3.857

5.  Nifedipine: kinetics and dynamics in healthy subjects.

Authors:  C H Kleinbloesem; P van Brummelen; J A van de Linde; P J Voogd; D D Breimer
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

6.  Changes in water and electrolyte balance, plasma volume and composition during pregnancy in the rat.

Authors:  J C Atherton; J M Dark; H O Garland; M R Morgan; J Pidgeon; S Soni
Journal:  J Physiol       Date:  1982-09       Impact factor: 5.182

7.  Calcium accumulation by human uterine microsomal preparations: Effects of progesterone and oxytocin.

Authors:  M E Carsten
Journal:  Am J Obstet Gynecol       Date:  1979-03-15       Impact factor: 8.661

8.  Serum protein binding of drugs during and after pregnancy in rats.

Authors:  B Stock; M Dean; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1980-02       Impact factor: 4.030

9.  Effects of nifedipine on spontaneous and methylergometrine-induced activity post partum.

Authors:  A Forman; P Gandrup; K E Andersson; U Ulmsten
Journal:  Am J Obstet Gynecol       Date:  1982-10-15       Impact factor: 8.661

10.  Comparative in vivo and in vitro studies of phenytoin protein binding and in vitro lipolysis in plasma of pregnant and nonpregnant rats.

Authors:  R C Chou; G Levy
Journal:  J Pharm Sci       Date:  1984-08       Impact factor: 3.534

View more
  3 in total

1.  Effects of calcium channel blockers on the development of early rat postimplantation embryos in culture.

Authors:  G Stein; M K Srivastava; H J Merker; D Neubert
Journal:  Arch Toxicol       Date:  1990       Impact factor: 5.153

2.  Effects of several potassium channel openers and glibenclamide on the uterus of the rat.

Authors:  I Piper; E Minshall; S J Downing; M Hollingsworth; H Sadraei
Journal:  Br J Pharmacol       Date:  1990-12       Impact factor: 8.739

3.  Tolerance to cromakalim in the rat uterus in vivo.

Authors:  S J Downing; M Miller; M Hollingsworth
Journal:  Br J Pharmacol       Date:  1989-03       Impact factor: 8.739

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.